Related Experiment Video
Updated: Aug 23, 2026

An Efficient and Rapid HPLC-QQQ-MS Method for the Quantitation of Tropane Alkaloids in Medicinal Plants
Published on: June 12, 2026
Investigation of quality in ephedrine-containing dietary supplements
John I Baker1, Xuewei Zhang, Tracey A Boucher
1Center for Addiction and Alternative Medicine Research, Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA. jbaker@mmrf.org
Abstract:
Ephedra alkaloids in 47 dietary supplements were measured to examine variability within and between products as well as for comparison of actual constituents with label claims of manufactured products. Samples were analyzed for (-)-ephedrine, (+)-pseudoephedrine, (-)-methylephedrine, (+)-methylpseudoephedrine,(-)-norephedrine, and (+)-norpseudoephedrine without derivatization using gas chromatographic mass spectrometry (GC/MS). Samples were then screened for pharmaceutically derived chiral contaminants. The resulting data demonstrated that label claims matched total ephedra alkaloid content to within about 25% for most of the supplements, and no products purporting to be ephedrine-free contained any ephedra alkaloids. Furthermore, chiral analysis of these dietary supplements revealed only naturally occurring ephedra alkaloids. (-)-Ephedrine and (+)-pseudoephedrine accounted for > 95% of the alkaloid content in each of the ephedra-containing products. Examination of identical supplements originating from different lots revealed consistency in total alkaloid content between lots but large variations in specific individual alkaloid content.
More Related Videos
Related Concept Videos
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Drug Regulation
Clinically Relevant Drug Product Specifications: Methods of Establishment

